scholarly journals #30: Coronavirus Disease 2019 (COVID-19) Incidence in Pediatric Oncology Patient: Does Routine Screening Affect the Risk for the Transmission in the Hospital

2021 ◽  
Vol 10 (Supplement_2) ◽  
pp. S18-S18
Author(s):  
Riyadi Adrizain ◽  
Nurmelani Sari
Keyword(s):  
Pediatric Oncology ◽  
Routine Screening ◽  
Oncology Patients ◽  
Oncology Patient ◽  
Pediatric Oncology Patient ◽  
Number Of Patients ◽  
Oncologic Patients ◽  
Boarding House ◽  
Second Period ◽  
Positive Results

Abstract Background Cancer patients are at higher risk of COVID-19 infection and more likely they have higher morbidity and mortality than the general population. On the other hand, the oncology patient sometimes can show asymptomatic COVID-19 disease with a risk of longer viral shedding and spreading the infection to others immunosuppressed individuals. Oncology patients also regularly travel between hospital and sometimes lodge in boarding house for routine chemotherapy. As we known, prevention strategy for COVID-19 among pediatric oncology patients can be implemented by minimizing these risks factors for transmission by identifying all patients infected with COVID-19. Here, we report our experience before and after implementing COVID-19 testing policy of patients with hematology and oncology diseases in our center. Method We collected data of pediatric oncology patients admitted to Hasan Sadikin General hospital between July 1st, 2020 to January 8th, 2021. The data consisted of the total number of patients and COVID-19 status by using SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) performed in the patient during two periods. In the first period, we performed NAAT if the patient was suspected of COVID-19. In the second period, after the policy was changed, NAAT was performed routinely as screening for all oncologic patients admitted to the hospital. Results Between July 1st to December 2nd, 2020, the first period, there was 3 positive results from 36 suspected COVID-19 patients among 181 total pediatric oncology patients. In the second period, we found 8 positive results from 121 hospitalized patients, none of them had signs and symptoms of COVID-19; and 4 of them came from boarding house. Conclusion Routine screening for COVID-19 should be considered as a policy for hospitalization of a pediatric oncology patient because of the high risk that asymptomatic COVID-19 patients can transmit the infection to other patient and to health care workers in the hospital.

Development of Electronic Chemotherapy Roadmaps for Pediatric Oncology Patients

2018 ◽  
Vol 35 (5) ◽  
pp. 314-319 ◽  
Author(s):  
Steven W. Allen ◽  
Robert J. Hayashi ◽  
Sally J. Jones ◽  
Mandy H. Drozda ◽  
Robert L. Brown ◽  
...  
Keyword(s):  
Patient Safety ◽  
Information Systems ◽  
Pediatric Oncology ◽  
Computer Application ◽  
Unintended Effects ◽  
Oncology Patients ◽  
Oncology Patient ◽  
Treatment Protocols ◽  
Pediatric Oncology Patient ◽  
Average Proportion

A chemotherapy roadmap is a summary of the chemotherapy plan for a pediatric oncology patient. Chemotherapy roadmaps exist as paper documents for most, if not all, pediatric oncology programs. Paper chemotherapy roadmaps are associated with risks that can negatively affect the safety of the chemotherapy process. This institution explored the feasibility of converting paper chemotherapy roadmaps into an electronic form. The pediatric information systems team developed an innovative computer application that can generate electronic chemotherapy roadmaps, and the pediatric oncology program established a novel workflow that can operationalize them. Electronic chemotherapy roadmaps have been produced for 36 treatment protocols, and 369 electronic chemotherapy roadmaps have been used for 352 pediatric oncology patients. They have functioned as designed and have not had any unintended effects. In the 5 years after their implementation, the average proportion of patient safety events involving paper or electronic chemotherapy roadmaps decreased by 78.7%. This report is the first to demonstrate the feasibility of creating and implementing electronic chemotherapy roadmaps. Continued expansion of the current library will be necessary to formally test the hypothesis that electronic chemotherapy roadmaps can decrease the risks associated with their paper counterparts and increase the safety of the chemotherapy process.

ED utilization trends for medical oncology patients at Thomas Jefferson University during COVID-19.

2020 ◽  
Vol 38 (29_suppl) ◽  
pp. 238-238
Author(s):  
Zachary L. Quinn ◽  
Adam Binder ◽  
Valerie Pracilio Csik ◽  
Helen Evers-Hunt ◽  
Nathan Handley
Keyword(s):  
Acute Care ◽  
Active Treatment ◽  
Medical Oncology ◽  
Healthcare Delivery ◽  
Thomas Jefferson ◽  
Care Utilization ◽  
Oncology Patients ◽  
Oncology Patient ◽  
Number Of Patients ◽  
Ed Visits

238 Background: For patients receiving cancer care, utilization of acute care resources can be frequent and, in many instances, is avoidable. At Thomas Jefferson University (TJU), up to 50% of emergency department (ED) visits for medical oncology patients on active treatment (receiving intravenous or oral chemotherapy within 30 days) may be preventable based on OP-35 criteria. The COVID-19 pandemic drastically altered healthcare delivery, prompting providers and patients to re-evaluate the safety and necessity of acute care. We aimed to evaluate the effect of the COVID-19 pandemic on ED utilization for medical oncology patients at TJU. Methods: We reviewed the total number of visits to the TJU ED for all patients and for medical oncology patients from January 1, to May 31, 2020. We defined the months of January and February as “Pre-COVID” and the months of April and May as “COVID”. We excluded data from March in our analysis. For medical oncology patients, we tallied both the number of patients with an ED visit and total ED visits for each month. We stratified patients by whether or not they were on active treatment. We reviewed the outcome of each ED visit and categorized results as admission (inpatient admission or observation) or discharge. We classified each ED visit as avoidable or unavoidable using OP-35 criteria. Results: In the Pre-COVID months there were 489 total visits by 432 oncology patients; 41% (179) of these patients were on active treatment. During COVID months there were 313 visits by 284 oncology patients; 48% (137) were on active treatment at the time of visit. During COVID, total ED visits decreased by 37%. Visits by medical oncology patients decreased by 35%. For medical oncology patients on active treatment, we observed a 21% reduction in ED visits. In the Pre-COVID months, 38% of oncology patient visits were considerable potentially avoidable and 41% of visits ended with a discharge to home. In comparison, during COVID, 31% of visits were considered potentially avoidable and 35% of visits ended with a discharge to home. Conclusions: We observed a decrease in ED utilization by oncology patients that mirrored decrease in total ED utilization following the COVID-19 outbreak. The decrease was less prominent for patients on active treatment. The percent of visits that were potentially avoidable and the percentage of patients discharged to home from the ED decreased slightly during the COVID period. Further analysis is ongoing to understand factors driving reduction in ED utilization observed immediately following the COVID-19 outbreak.

scholarly journals Bezoar in a Pediatric Oncology Patient Treated with Coca-Cola

2015 ◽  
Vol 9 (2) ◽  
pp. 227-232 ◽  
Author(s):  
Sara Naramore ◽  
Amy Virojanapa ◽  
Moshe Bell ◽  
Punit N. Jhaveri
Keyword(s):  
Abdominal Pain ◽  
Pediatric Patient ◽  
Pediatric Oncology ◽  
Gastrointestinal Symptoms ◽  
Nausea And Vomiting ◽  
Diagnosis And Treatment ◽  
Intestinal Bleeding ◽  
Oncology Patient ◽  
Pediatric Oncology Patient ◽  
Gradual Onset

A bezoar is a mass of indigestible material. Bezoars can present with a gradual onset of non-specific gastrointestinal symptoms including abdominal pain, nausea and vomiting. However, bezoars can result in more serious conditions such as intestinal bleeding or obstruction. Without quick recognition, particularly in susceptible individuals, the diagnosis and treatment can be delayed. Currently resolution is achieved with enzymatic dissolution, endoscopic fragmentation or surgery. We describe, to our knowledge, the first pediatric patient with lymphoma to have had a bezoar treated with Coca-Cola.

scholarly journals Herbaspirillum Species Bacteremia in a Pediatric Oncology Patient

2010 ◽  
Vol 48 (11) ◽  
pp. 4320-4321 ◽  
Author(s):  
E. D. Ziga ◽  
T. Druley ◽  
C.-A. D. Burnham
Keyword(s):  
Pediatric Oncology ◽  
Oncology Patient ◽  
Pediatric Oncology Patient
Sign in / Sign up

Export Citation Format

Share Document